#pibrentasvir

The Food and Drug Administration (FDA) recently approved AbbVie’s Mavyret, the newest treatment for chronic hepatitis C.

Mavyret taken for eight weeks was well tolerated and cured all HIV-positive people without cirrhosis in a recent study

Maviret and Vosevi were highly effective and well tolerated in clinical trials.

Glecaprevir/pibrentasvir (G/P) cured high rates of those with genotype 1 who failed a previous hep C cure attempt in a Phase II study.

The single-pill regimen would provide an eight-week ribavirin-free option for those with all viral genotypes who do not have cirrhosis.

The once-daily investigational hepatitis C virus (HCV) combination tablet will likely be approved in 2017.

AbbVie’s investigational hepatitis C virus (HCV) treatment is poised for approval in 2017.

The investigational glecaprevir/pibrentasvir performed very well among the historically hard-to-treat group, including those with cirrhosis.

AbbVie’s investigational daily, fixed-dose combination tablet performed very well among those with milder liver damage.

The FDA grants breakthrough therapy designation to AbbVie’s experimental hepatitis C regimen glecaprevir/pibrentasvir